Horizon Pharma , Nasdaq: HZNP
Launching DUEXIS for pain relief in rheumatoid arthritis/osteoarthritis patients.
Industry: Health Care
First Day Return: +1.7%
HZNP
Launching DUEXIS for pain relief in rheumatoid arthritis/osteoarthritis patients.
| IPO Data | |
|---|---|
| IPO Date | 07/27/2011 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Northbrook, IL, United States |
| Founded | 2005 |
| Employees at IPO | 39 |
| Website www.horizonpharma.com | |
IPO News for Horizon Pharma
Horizon Pharma (HZNP) Performance
